Table 10.
Clinical and pathological parameters of patients (n = 33) studied and the Association of pre-NAC tumour-infiltrating CD163+ macrophages (TIMs) and pathological complete response (PCR).
| Groups | TIMs | PCR | ||||||
|---|---|---|---|---|---|---|---|---|
| Low infiltration (n) | High infiltration (n) | Pearson chi-square value | p value | Non-PCR (n) | PCR (n) | Pearson chi-square value | p value | |
| Age (years) | ||||||||
| <50 | 6 | 8 | 0.002 | 0.966 | 8 | 6 | 0.308 | 0.579 |
| ≥50 | 8 | 11 | 9 | 10 | ||||
| BMI (kg/m2) | ||||||||
| ≤30 | 10 | 10 | 1.193 | 0.275 | 11 | 9 | 0.247 | 0.619 |
| >30 | 4 | 9 | 6 | 7 | ||||
| Menopausal status | ||||||||
| Pre | 5 | 11 | 1.588 | 0.208 | 8 | 8 | 0.029 | 0.866 |
| Post | 9 | 8 | 9 | 8 | ||||
| Tumour size | ||||||||
| <40 mm | 8 | 10 | 0.066 | 0.797 | 9 | 9 | 0.036 | 0.849 |
| ≥40 mm | 6 | 9 | 8 | 7 | ||||
| Nodal status | ||||||||
| Negative | 5 | 5 | 0.337 | 0.561 | 5 | 5 | 0.013 | 0.909 |
| Positive | 9 | 14 | 12 | 11 | ||||
| Tumour grade | ||||||||
| 1 (low) | 1 | 1 | 11.270 | 0.004∗ | 2 | 0 | 9.303 | 0.010∗ |
| 2 (moderate) | 10 | 3 | 10 | 3 | ||||
| 3 (high) | 3 | 15 | 5 | 13 | ||||
| Oestrogen receptor | ||||||||
| Negative | 2 | 9 | 3.970 | 0.046∗ | 3 | 8 | 3.882 | 0.049∗ |
| Positive | 12 | 10 | 14 | 8 | ||||
| HER-2 receptor | ||||||||
| Negative | 10 | 13 | 0.035 | 0.853 | 13 | 10 | 0.762 | 0.383 |
| Positive | 4 | 6 | 4 | 6 | ||||
| NAC regimen | ||||||||
| AC-TX | 6 | 10 | 0.308 | 0.579 | 6 | 10 | 2.443 | 0.118 |
| AC-T | 8 | 9 | 11 | 6 | ||||
| Recurrent disease(4) | ||||||||
| No | 8 | 14 | 0.992 | 0.319 | 7 | 15 | 10.252 | 0.001∗ |
| Yes | 6 | 5 | 10 | 1 | ||||
| Death(4) | ||||||||
| No | 11 | 16 | 0.172 | 0.678 | 12 | 15 | 2.972 | 0.085 |
| Yes | 3 | 3 | 5 | 1 | ||||
NAC: neoadjuvant chemotherapy; BMI: body mass index (≤30: nonobese, >30: obese); AC-TX: doxorubicin, cyclophosphamide, taxotere, and xeloda® (capecitabine), respectively; (4)4-year follow-up; ∗statistically significant.